Lynn Stockwell - 29 Jan 2025 Form 4 Insider Report for Drugs Made In America Acquisition Corp. (DMAA)

Role: CEO and Executive COB, Director, 10%+ Owner
Signature: /s/ Lynn Stockwell
Issuer symbol: DMAA
Transactions as of: 29 Jan 2025
Net transactions value: $0
Form type: 4
Filing time: 04 Feb 2025, 19:40:17 UTC
Previous filing: 10 Jan 2025
Next filing: 18 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DMAA	Ordinary shares	Purchase		+400,000			10,257	29 Jan 2025	See footnote	F1
transaction	DMAA	Ordinary shares	Other		-400,000	-3.9%		9,857,143	29 Jan 2025	See footnote	F1, F2
transaction	DMAA	Ordinary shares	Sale		-5,698,363	-58%		4,158,780	29 Jan 2025	See footnote	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DMAA	Rights to receive ordinary shares	Purchase		+400,000			400,000	29 Jan 2025	Ordinary shares	400,000		See footnote	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the 400,000 private units owned by Drugs Made In America Acquisition LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $4,000,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.
F2	As of the Transaction Date, the sponsor transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration.
F3	As of the Transaction Date, pursuant to share transfer agreements, the sponsor transferred an aggregate of 5,698,363 ordinary shares for consideration ranging from no consideration to $1.50 per share.
F4	The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.